HIV / hepatitis B / hepatitis C post-exposure prophylaxis
PEP · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
After occupational (needlestick) or non-occupational (sexual, injecting) exposure to blood/body fluids, rapid risk assessment guides HIV post-exposure prophylaxis and hepatitis B/C management. HIV PEP is time-critical and most effective started within hours, and useless beyond 72 hours.
Red flags
- Presentation beyond 72 h for HIV exposure (PEP no longer effective)
- Deep injury with hollow-bore blood-filled needle from viraemic source
- Known resistant source HIV virus (seek specialist regimen)
- Established acute HIV symptoms
- Pregnancy requiring tailored regimen
Assessment
Differential diagnosis
- Negligible-risk exposure not needing PEP
- Source known HIV positive and suppressed (lower risk)
- High-risk mucosal/percutaneous HIV exposure
- Hepatitis B exposure in non-immune person
- Hepatitis C exposure (no prophylaxis, monitor)
Investigations
- Baseline HIV antigen/antibody of exposed person
- Hepatitis B surface antibody/antigen and core status
- Hepatitis C antibody (and source where consentable)
- Renal and liver function before PEP
- Pregnancy test
- Source testing where possible (HIV, HBsAg, HCV)
Management
- Perform first aid: wash wound, irrigate mucosa; do not squeeze/suck
- Risk-assess exposure type, fluid and source status urgently
- If HIV risk significant, start PEP immediately (within 72 h, ideally hours)
- Send baseline bloods; obtain source-patient testing with consent
- For hepatitis B: give accelerated vaccine +/- immunoglobulin based on immunity and source
- No prophylaxis for hepatitis C; arrange monitoring and early treatment if seroconversion
- Counsel on adherence, side effects, and safe sex/no donation during follow-up
- Provide emergency contraception and STI screening after sexual exposure
- Review at 48-72 h to confirm indication and tolerability
- Continue HIV PEP for 28 days
- Repeat HIV test at 6-8 weeks (and 12 weeks if indicated); hepatitis C RNA/antibody follow-up
- Refer occupational exposures to occupational health
Drugs & doses
Tenofovir disoproxil/emtricitabine 245/200 mg PO once daily plus raltegravir 400 mg PO twice daily (or dolutegravir 50 mg once daily) for 28 days
Hepatitis B immunoglobulin 500 units IM (within 48 h) if non-immune and source infectious
Hepatitis B vaccine accelerated schedule 0, 1, 2 months (plus 12 months)
Emergency contraception (levonorgestrel 1.5 mg PO) after sexual exposure as needed
Disposition
Emergency department / occupational health / sexual health; urgent start then specialist follow-up.
Complications & pitfalls
- HIV seroconversion despite PEP (adherence/resistance)
- PEP gastrointestinal/renal side effects and non-completion
- Hepatitis B acquisition in unprotected person
- Hepatitis C chronic infection
- Anxiety and loss to follow-up
Exam pearls
- Start PEP first, refine regimen later once source status known
- If source is HIV positive with confirmed undetectable load, PEP often not required
- Hepatitis C has no prophylaxis but highly curable if detected early
- Document all occupational exposures and report per local policy
- Confirm hepatitis B immunity with anti-HBs level where possible
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.